Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 2, 2026
Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Fineline Cube Mar 2, 2026
Company Drug

Inmagene Biopharmaceuticals Posts Positive Results for IMG-007 in Atopic Dermatitis

Fineline Cube Jan 10, 2025

Inmagene Biopharmaceuticals, a Sino-US biotech that recently merged with US-based Ikena Oncology, Inc. (NASDAQ: IKNA),...

Company Deals

BrainAurora Medical Technology IPOs on Hong Kong Stock Exchange

Fineline Cube Jan 10, 2025

Zhejiang-based BrainAurora Medical Technology Limited (HKG: 6681), the first company in China to combine neuroscience...

Policy / Regulatory

NMPA Releases 89th Batch of Reference Drugs for GQCE Work

Fineline Cube Jan 10, 2025

The National Medical Products Administration (NMPA) has released the 89th batch of reference drugs for...

Policy / Regulatory

China’s NHC Aims for Over 90% Child-Friendly Hospitals by 2030

Fineline Cube Jan 10, 2025

The Department of Maternal and Child Health Care of the National Healthcare Commission (NHC) has...

Company Deals

Stryker to Acquire Inari Medical for USD 4.9 Billion to Boost VTE Pipeline

Fineline Cube Jan 10, 2025

US-based Stryker (NYSE: SYK) has reached a definitive acquisition agreement with compatriot firm Inari Medical,...

Company Drug

GSK Launches Cabotegravir Injection in China for HIV Pre-Exposure Prophylaxis

Fineline Cube Jan 10, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection...

Company Deals

Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong

Fineline Cube Jan 10, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in...

Company Deals

Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS

Fineline Cube Jan 9, 2025

Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS...

Company Drug

NHSA Revises 2024 NRDL Drug Information Based on Public Feedback

Fineline Cube Jan 9, 2025

China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs...

Company

Eli Lilly China’s Neuroscience VP Jiang Yifei Departs for New Opportunities

Fineline Cube Jan 9, 2025

Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has...

Company Deals

Fourier Intelligence Secures USD 109 Million in Series E Funding for Robotics Innovation

Fineline Cube Jan 9, 2025

China-based Shanghai Fourier Intelligence Co., Ltd, a leading developer of exoskeleton robotic products for rehabilitation...

Company Drug

Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer

Fineline Cube Jan 9, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...

Company Drug

HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy

Fineline Cube Jan 9, 2025

Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines...

Company Deals

China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia

Fineline Cube Jan 9, 2025

China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition...

Company Deals

Huahai Pharmaceutical to Transfer Rights to Innovative Antidepressant HHT001 via Public Listing

Fineline Cube Jan 9, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is set to transfer the patent and...

Company Drug

Mabwell’s 9MW2821 Granted Breakthrough Therapy Designation by CDE for Urothelial Carcinoma

Fineline Cube Jan 9, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that the Center for Drug...

Company Drug

Kelun Pharmaceutical’s Generic Mulpleta Gains NMPA Approval in China

Fineline Cube Jan 9, 2025

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that it has received marketing...

Company Deals

Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform

Fineline Cube Jan 9, 2025

US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ:...

Company Drug

Fujian Cosunter’s COVID-19 Therapy GST-HG171/ritonavir Approved in Macau

Fineline Cube Jan 9, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that its Category 1 product,...

Company Medical Device

Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment

Fineline Cube Jan 9, 2025

US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System...

Posts pagination

1 … 193 194 195 … 628

Recent updates

  • Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy
  • HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline
  • Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.